Biotech Values

[rkrw]

AGIX.

20% reduction over and above statins doesn't seem like a trivial target either. Will 4,000 patients be enough to reach significance?

Certainly arise isn't without risk.

I also wonder about the 450 odd patients they followed in cart II. Surely they must have some sort of data on their events and outcomes over their 12 months of therapy?